BrightInsight adds medical device and biopharmaceutical experts Tamara Elias, MD and Scott Huennekens to the Advisory Board

SAN JOSE, California —

BrightInsight, Inc., Provider of the leading global platform for biopharmaceutical and medical device-regulated digital health solutions, today announced the appointment of Tamara Elias, MD, Senior Vice President at Nuance and Scott Hunnekens, CEO of Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. dr Elias and Huennekens bring deep and complementary experiences to this group of industry professionals who will work with BrightInsight leadership to advance the company’s vision of improving patient outcomes worldwide through the power of digital technology.

dr Elias and Huennekens join the advisory board as BrightInsight further solidifies its position as the de facto digital health platform for biopharma and medtech. A new biopharma partnership for BrightInsight was announced in the first half of 2022, with Sanofi adding to its client list that includes CSL Behring, Roche, Novo Nordisk, and others. The company also recently launched BrightInsight Networked diagnostic platform for in vitro diagnostics and their digital Disease Management Solution.

“We are very pleased that Dr. Tamara Elias and Scott Huennekens join our Advisory Board and provide insights based on their decades of leadership in digital innovation and adoption in the life sciences,” said Kal Patel, MD, CEO and co-founder of BrightInsight. “Our team and customers will benefit from their advice as we continue to grow internationally and expand our portfolio of digital health solutions.”

Tamara Elias, MD, has been deeply involved in healthcare for over 20 years and brings a wide range of diverse experiences from medical school through residency training, followed by strategic healthcare consulting, private equity investing, corporate strategy and business development and product innovation, including board positions. Currently, as Senior Vice President, Strategy and Business Incubation at Nuance Communications, a Microsoft company, she orchestrates complex processes and initiatives to understand how the unique assets of these two companies can be leveraged to drive workflows and diagnostics across the ecosystem to improve healthcare. In her previous role at Merck, she was Vice President of Global Partnerships & Innovation and implemented “all around the pill” innovations for her stakeholders. Prior to Merck, she was vice president of clinical product development at Aetna and vice president, strategy and business development at Becton Dickinson. Earlier in her career, she was a partner at Essex Woodlands Health Partners, McKinsey executive and general surgeon. She currently serves on the boards of directors of Avinger (NASDAQ:AVGR), REVA Medical LLC and BehaVR.

“Digital touches every area of ​​healthcare, including biopharma, that traditionally lacks expertise in regulated platforms,” ​​said Tamara Elias, MD. I look forward to joining the BrightInsight Advisory Council and working with the team to advance the adoption of digital technologies in the life sciences industry.”

Scott is a veteran medtech CEO, chairman, board member, entrepreneur, and investor who has served in one of these roles for more than 20 startup, growth, and public companies with aggregate market valuations in excess of $20 billion. He is currently executive chairman of Hyperfine (NASDAQ: HYPR), chairman of Acutus Medical (NASDAQ: AFIB), chairman of Envista (NYSE: NVST), board member of Nuvasive (NASDAQ: NUVA), and executive chairman and investor of Wondr Medical. Over 20 million patients have benefited from the therapies and diagnostics of the companies in which Scott has been a part.

“As the medtech industry advances, everything revolves around digitization, with the guiding principle being connectivity, which enables data to be collected and enabled,” said Scott Huennekens. “It is important for medical technology to share data across the continuum of care to foster collaboration, enable better care and reduce costs. Achieving these goals requires a regulated digital health platform to ensure medtech and diagnostics companies comply with quality, security, regulatory, and privacy requirements. I’m excited to join the BrightInsight Advisory Council and work with the team to continue to improve and customize their offerings for innovative medtech companies.”

BrightInsight and its customers completed seven Software as a Medical Device (SaMD) projects in 2021. The company is expanding its footprint around the world with team members in the United States, Europe and India.

###

The BrightInsight Advisory Board includes some of the world’s most accomplished thought leaders in healthcare, technology and business including Mark T. Bertolini, Karl Hick, Donald Jones, Jeffrey Leiden, MD, Ph.D., Diana McKenzie, Kim Powell, Brent Saunders, Meinhard F. Schmidt , Jagjot (JJ) Singh, Bradley Stock, Hemant Taneja and Elisabethann Wright.

BrightInsight provides the leading global platform for biopharma and medical device regulated digital health solutions. When speed matters, we help companies accelerate time to market for regulated digital health offerings across therapeutic areas including apps, healthcare provider interfaces, analytics dashboards, algorithms, medical devices, connected combination products, diagnostics and software as a medical device (SaMD) . BrightInsight replaces the need for lengthy and complex “build from scratch” implementations by offering configurable software solutions and a proven platform built on Google Cloud under a quality management system to support global security, privacy and regulatory requirements. When creating digital health products on the BrightInsight platform, compliance is future-proof as intended use changes across different regions.

For more information, see BrightInsight website, to blog, Twitterand LinkedIn Pages.

Comments are closed.